Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma
Clinical trial NCT04961515 · RECRUITING
Trial details
- NCT number
- NCT04961515
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-01
- Primary completion
- 2025-12-31
- Enrollment
- 19
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.